Recombinant human nerve growth factor in the treatments of diabetic polyneuropathy

Neurology

Volumn 51, Issue 3, 1998, Pages 695-702

  Apfel, S C ^a   Kessler, J A ^a   Adornato, B T ^b   Litchy, W J ^c   Sanders, C ^d   Rask, C A ^d  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^b STANFORD UNIVERSITY   (United States)

^c Health Partners   (United States)

^d GENENTECH INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NERVE GROWTH FACTOR; PLACEBO;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETIC NEUROPATHY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; NERVE DEGENERATION; NEUROLOGIC EXAMINATION; PERIKARYON; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RETROGRADE NERVE FIBER TRANSPORT; SUBCUTANEOUS DRUG ADMINISTRATION;

EID: 0031752714     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/WNL.51.3.695     Document Type: Article

References (45)

1. Thomas PK, Tomlinson DR. Diabetic and hypoglycemic neuropathy. In: Dyck PJ, Thomas PK, Griffin JW, et al. Peripheral neuropathy. 3rd ed. Philadelphia: WB Saunders, 1993: 1219-1250.
2. Parkhouse N, Le Quesne PM. Impaired neurogenic vascular response in patients with diabetes and neuropathic foot lesions. N Engl J Med 1988;318:1306-1309.
3. Guy RJ, Clark CA, Malcolm PN, Watkins PJ. Evaluation of thermal and vibration sensation in diabetic neuropathy. Diabetologia 1985;28:131-137.
4. Young RJ, Zhou YQ, Rodriguez E, et al. Variable relationship between peripheral somatic and autonomic neuropathy in patients with different syndromes of diabetic polyneuropathy. Diabetes 1986;35:192-197.
5. Brown MJ, Martin JR, Asbury AK. Painful diabetic neuropathy: a morphometric study. Arch Neurol 1976;33:164-171.
6. Cohen S, Levi-Montalcini R, Hamburger V. A nerve growth stimulating factor isolated from sarcomas 37 and 180. Proc Natl Acad Sci USA 1954;40:1014-1018.
7. Levi-Montalcini R. The nerve growth factor 35 years later. Science 1987;237:1154-1162.
8. Rohrer H, Heumann R, Thoenen H. The synthesis of nerve growth factor (NGF) in developing skin is independent of innervation. Dev Biol 1988;128:240-244.
9. Stockel K, Paravicini U, Thoenen H. Specificity of the retrograde axonal transport of nerve growth factor. Brain Res 1974;76:413-421.
10. Hellweg R, Hartung HD. Endogenous levels of nerve growth factor (NGF) are altered in experimental diabetes mellitus: a possible role for NGF in the pathogenesis of diabetic neuropathy. J Neurosci Res 1990;26:258-267.
11. Jakobsen J, Brimijoin S, Skau K, Sidenius P, Wells D. Retrograde axonal transport of transmitter enzymes, fucose labeled protein and nerve growth factor in streptozocin-diabetic rats. Diabetes 1981;30:797-803.
12. 125I nerve growth factor in ileal mesenteric nerves in vitro: effect of streptozocin diabetes. Brain Res 1986;378:325-336.
13. Hellweg R, Raivich G, Hartung HD, Hock C, Kreutzberg GW. Axonal transport of endogenous nerve growth factor (NGF) and NGF receptor in experimental diabetic neuropathy. Exp Neurol 1994;130:24-30.
14. Fernyhough P, Diemel LT, Brewster WJ, Tomlinson DR. Deficits in sciatic nerve neuropeptide content coincide with a reduction in target tissue nerve growth factor messenger RNA in streptozocin-diabetic rats: effects of insulin treatment. Neuroscience 1994;62:337-344.
15. Ordonez G, Fernandez A, Perez R, Sotelo J. Low contents of nerve growth factor in serum and submaxillary gland of diabetic mice: a possible etiological element of diabetic neuropathy. J Neurol Sci 1994;121:163-166.
16. Kasayama S, Oka T. Impaired production of nerve growth factor in the submandibular gland of diabetic mice. Am J Physiol 1989;257:E400-E404.
17. Anand P, Terenghi G, Warner G, Kopelman P, Williams Chestnut RE, Sinicropi DV. The role of endogenous nerve growth factor in human diabetic neuropathy. Nature Med 1996;2:703-707.
18. Apfel SC, Lipton RB, Arezzo JC, Kessler JA. Nerve growth factor prevents toxic neuropathy in mice. Ann Neurol 1991;29: 87-89.
19. Apfel SC, Arezzo JC, Lipson L, Kessler JA. Nerve growth factor prevents experimental cisplatin neuropathy. Ann Neurol 1992;31:76-80.
20. Apfel SC, Arezzo JC, Brownlee M, Federoff H, Kessler JA. Nerve growth factor administration protects against experimental diabetic sensory neuropathy. Brain Res 1994;634: 7-12.
21. Petty BG, Cornblath DR, Adornato BT, et al. The effect of systemically administered recombinant human nerve growth factor in healthy human subjects. Ann Neurol 1994;36:244-246.
22. Dyck PJ, Karnes JL, Daube J, O'Brien PC, Service FJ. Clinical and neuropathological criteria for diagnosis and staging of diabetic neuropathy. Brain 1985;108:861-880.
23. Dyck PJ, Karnes JL, O'Brien PC, Litchy WJ, Low PA, Melton LJ. The Rochester diabetic neuropathy study: reassessment of tests and criteria for diagnosis and staged severity. Neurology 1992;42:1164-1170.
24. Dyck PJ, Litchy WJ, Lehman KA, Hokanson BA, Low PA, O'Brien PC. Variables influencing neuropathic endpoints: the Rochester diabetic neuropathy study of healthy subjects. Neurology 1995;45:1115-1121.
25. Dyck PJ, Karnes JL, O'Brien PC, Swanson CJ. Neuropathy symptom profile in health, motor neuron disease, diabetic neuropathy, and amyloidosis. Neurology 1986;36:1300-1308.
26. Dyck PJ, Bushek W, Spring EM, et al. Vibratory and cooling detection thresholds compared with other tests in diagnosing and staging diabetic neuropathy. Diabetes Care 1987;10:432-440.
27. Dyck PJ, Zimmerman I, Gillen DA, Johnson BS, Karnes JL, O'Brien PC. Cool, warm and heat-pain detection thresholds: testing methods and inferences about anatomic distribution of receptors. Neurology 1993;43:1500-1508.
28. Gruener G, Dyck PJ. Quantitative sensory testing: methodology, applications, and future directions. J Clin Neurophysiol 1994;11:568-583.
29. Dyck PJ, O'Brien PC, Kosanke JL, Gillen DA, Karnes JL. A 4,2, and 1 stepping algorithm for quick and accurate estimation of cutaneous sensation threshold. Neurology 1993;43: 1508-1512.
30. Dyck PJ, Zimmerman IR, Johnson DM, et al. A standard test of heat pain response using CASE IV. J Neurol Sci 1996;136: 54-63.
31. Dyck PJ, Davies JL, Litchy MD, O'Brien PC. Longitudinal assessment of diabetic polyneuropathy using a composite score in the Rochester Diabetic Neuropathy Study cohort. Neurology 1997;49:229-239.
32. Peace KE, ed. Biopharmaceutical statistics for drug development. New York: Marcel Dekker, 1998.
33. O'Brien P. Procedures for comparing samples with multiple endpoints. Biometrics 1984;40:1079-1087.
34. Apfel S, Adornato B, Cornblath D, et al. Clinical trial of recombinant human nerve growth factor (rhNGF) in peripheral neuropathy. Neurology 1995;45(suppl 4):A278-A279.
35. Conti AM, Fischer SJ, Windebank AJ. Inhibition of axonal growth from sensory neurons by excess nerve growth factor. Ann Neurol 1997;42:838-846.
36. Kessler JA, Black IB. Nerve growth factor stimulates the development of substance P in sensory ganglia. Proc Natl Acad Sci USA 1980;77:113-122.
37. MacLean DB, Bennett B, Morris M, Wheeler FB. Differential regulation of calcitonin gene related peptide and substance P in cultured neonatal rat vagal sensory neurons. Brain Res 1989;478:349-355.
38. Tiercy JM, Shooter EM. Early changes in the synthesis of nuclear and cytoplasmic proteins are induced by nerve growth factor in differentiating rat PC12 cells. J Cell Biol 1986;103: 2367-2378.
39. Diamond J, Holmes M, Coughlin M. Endogenous NGF and nerve impulses regulate the collateral sprouting of sensory axons in the skin of the adult rat. J Neurosci 1992;12:1454-1466.
40. Jackson GR, Apffel L, Werrbach-Perez K, Perez-Polo JR. Role of nerve growth factor in oxidant-antioxidant balance and neuronal injury. I. Stimulation of hydrogen peroxidase resistance J Neurosci Res 1990;25:360-368.
41. Diemel LT, Brewster WJ, Fernyhough P, Tomlinson DR. Expression of neuropeptides in experimental diabetes; effects of treatment with nerve growth factor or brain derived neurotrophic factor. Mol Brain Res 1994;21:171-175.
42. Lewin GR, Ritter A, Mendell LM. Nerve growth factor-induced hyperalgesia in the neonatal and adult rat. J Neurosci 1993;13:2136-2148.
43. Lewin GR Rueff A, Mendell LM. Peripheral and central ' mechanisms of NGF induced hyperalgesia. Eur J Neurosci 1994;6:1903-1912.
44. Lewin GR, Mendell LM. Nerve growth factor and nociception. Trends Neurosci 1993;16:353-359.
45. Apfel SC, Newel M, Dormia C, Kessler JA. Kappa opioid receptors participate in nerve growth factor-induced hyperalgesia. Neuroscience 1995;68:1199-1206.